Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters
- 1 September 2000
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 58 (3) , 641-648
Abstract
The antiviral activity of l-chicoric acid against HIV-1 has been attributed previously to the inhibition of HIV-1 integration. This conclusion was based on the inhibition of integrase activity in enzymatic assays and the isolation of a resistant HIV strain with a mutation (G140S) in the integrase gene. Here we show that the primary antiviral target of l-CA and its analogs in cell culture is viral entry. l- and d-chicoric acid (l-CA and d-CA) and their respective tetra-acetyl esters inhibit the replication of HIV-1 (IIIBand NL4.3) and HIV-2 (ROD) in MT-4 cells at a 50% effective concentration (EC50) ranging from 1.7 to 70.6 μM. In a time-of-addition experiment, l-CA, d-CA,l-CATA, and d-CATA were found to interfere with an early event in the viral replication cycle. Moreover,l-CA, d-CA, and their analogs did not inhibit the replication of virus strains that were resistant toward polyanionic and polycationic compounds at subtoxic concentrations. Furthermore, HIV-1 strains resistant to l-CA and d-CA were selected in the presence of l-CA and d-CA, respectively. Mutations were found in the V2, V3, and V4 loop region of the envelope glycoprotein gp120 of the l-CA andd-CA-resistant NL4.3 strains that were not present in the wild-type NL4.3 strain. Recombination of the gp120 gene of the l-CA and d-CA resistant strain in a NL4.3 wild-type molecular clone fully rescued the phenotypic resistance toward l-CA and d-CA. No significant mutations were detected in the integrase gene of the drug-resistant virus strains. Although inhibition of HIV integrase activity byl-CA and its derivatives was confirmed in an oligonucleotide-driven assay, integrase carrying the G140S mutation was inhibited to the same extent as the wild-type integrase.Keywords
This publication has 39 references indexed in Scilit:
- Assays for the Evaluation of HIV-1 Integrase Inhibitors2000
- High-level expression of active HIV-1 integrase from a synthetic gene in human cellsThe FASEB Journal, 2000
- Green coffee beans may yield new class of anti-HIV-1 agentsThe Lancet, 1998
- Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir)Molecular Pharmacology, 1998
- Mode of Interaction of G-Quartets with the Integrase of Human Immunodeficiency Virus Type 1Molecular Pharmacology, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Development of Resistance of Human Immunodeficiency Virus Type 1 to Dextran Sulfate Associated with the Emergence of Specific Mutations in the Envelope gp120 GlycoproteinMolecular Pharmacology, 1997
- Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)-Linked Bis-Tetraazamacrocycles That Inhibit HIV Replication. Effects of Macrocyclic Ring Size and Substituents on the Aromatic LinkerJournal of Medicinal Chemistry, 1995
- Long-term Persistent Infection of Macaque Monkeys with the Simian Immunodeficiency VirusJournal of General Virology, 1987
- Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)Science, 1983